Trial Profile
An Open-label, Randomized, Active-controlled, Parallel-group, Phase-3b Study of the Efficacy, Safety, and Tolerability of Three Different Treatment Regimens of 2 mg Aflibercept Administered by Intravitreal Injections to Subjects With Diabetic Macular Edema (DME)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms VIOLET
- Sponsors Bayer HealthCare
- 12 Apr 2022 Primary endpoint (Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52) has been met according to the results published in the Advances in Therapy
- 12 Apr 2022 Results published in the Advances in Therapy
- 24 Oct 2019 Status changed from active, no longer recruiting to completed.